A molecular clue to uneven disease severity

Facioscapulohumeral muscular dystrophy, or FSHD, can look dramatically different even among relatives who carry the same disease-causing genetic change. In a new study of a nine-generation family, researchers report that a DNA modification called methylation is strongly associated with that difference in severity.

The finding addresses a long-standing question in FSHD: why do some people develop early, severe weakness while others remain mildly affected for decades? The researchers say the result could support better predictions of disease course, improve the design of clinical trials and point toward future therapeutic targets.

Same inherited change, different outcomes

FSHD progressively weakens muscles of the face, shoulders and limbs. The report describes two siblings who inherited the same disease-causing change but experienced very different outcomes. The brother noticed weakness in his early teens and could barely walk by his 50s. His sister had no symptoms into her late 30s and remained only mildly affected throughout her life.

Such variation has been a defining challenge for patients, families and clinicians. The inherited change linked to FSHD affects DUX4, a gene that is normally active only during early embryonic development. In people with FSHD, DUX4 becomes active in adulthood as well, contributing to disease.

Genetic "dimmer switch" can protect against severe disease in rare muscular dystrophy
1953. Geneticist Dr. Fayette Stephens displays one of the first family trees from the same family with FSHD that continues to work with researchers today. Credit: Utah Historical Society

Methylation as a genetic dimmer

The new work identifies methylation as a factor that can act like a dimmer switch at the disease-causing genetic change. Higher or otherwise protective methylation patterns appear to reduce the impact of the underlying FSHD mechanism, making symptoms milder.

The study does not change the fact that people carrying the disease-causing change develop FSHD. Instead, it offers an explanation for why the disease can progress so differently from one affected person to another. Researchers had suspected methylation could play a role, but the family analysis provides clearer evidence connecting it to clinical severity.

Potential impact for care and research

Predicting the course of a rare genetic disease is difficult when the same genetic diagnosis can lead to widely different experiences. A methylation-based signal could eventually help clinicians and patients better understand likely disease severity. It may also help researchers group participants more effectively in clinical trials, where major differences in baseline progression can complicate efforts to evaluate treatments.

Genetic "dimmer switch" can protect against severe disease in rare muscular dystrophy
1953. Geneticist Dr. Fayette Stephens examines the same medical records, from the same family, that would help reveal the secrets of FSHD 70 years later. Credit: Utah Historical Society

The study was led by researchers at University of Utah Health and published in Brain. Its conclusions are based on a family that has contributed to FSHD research across generations, giving investigators an unusually long view of how the disorder appears in related people.

A path toward more precise FSHD research

The result points to regulation of DUX4 activity as an important part of the disease story. While the inherited genetic change establishes FSHD risk, methylation may influence how strongly the disease mechanism is expressed over a person’s life.

That distinction could matter for the next phase of FSHD research. Treatments aimed at reducing harmful DUX4 activity, or at understanding the molecular conditions that limit it, may benefit from taking methylation into account. More work will be needed to determine how broadly the finding applies beyond the family studied and how it can be used in patient care.

For now, the research offers a clearer biological explanation for a painful uncertainty faced by many families with FSHD: a shared diagnosis does not necessarily mean a shared outcome.

This article is based on reporting by Medical Xpress. Read the original article.

Originally published on medicalxpress.com